IGC PHARMA, INC. — Operating Income by Fiscal Year
15 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/27c774c1-5522-4eed-9679-9925724a56b7/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-7.4M | 2024-04-01 – 2025-03-31 | evidence 0001185185-25-000706 |
| FY 2023 | $-9.8M | 2023-04-01 – 2024-03-31 | evidence 0001185185-24-000650 |
| FY 2022 | $-11.6M | 2022-04-01 – 2023-03-31 | evidence 0001185185-23-000693 |
| FY 2021 | $-15.4M | 2021-04-01 – 2022-03-31 | evidence 0001185185-22-000768 |
| FY 2020 | $-8.7M | 2020-04-01 – 2021-03-31 | evidence 0001185185-21-000802 |
| FY 2019 | $-6.9M | 2019-04-01 – 2020-03-31 | evidence 0001185185-20-000984 |
| FY 2018 | $-4.6M | 2018-04-01 – 2019-03-31 | evidence 0001185185-19-000890 |
| FY 2017 | $-1.8M | 2017-04-01 – 2018-03-31 | evidence 0001185185-19-000890 |
| FY 2016 | $-2.1M | 2016-04-01 – 2017-03-31 | evidence 0001185185-17-001544 |
| FY 2015 | $-2.9M | 2015-04-01 – 2016-03-31 | evidence 0001185185-16-004982 |
| FY 2014 | $-4.3M | 2014-04-01 – 2015-03-31 | evidence 0001185185-15-001808 |
| FY 2013 | $-2.5M | 2013-04-01 – 2014-03-31 | evidence 0001185185-14-001804 |
| FY 2012 | $-2.5M | 2012-04-01 – 2013-03-31 | evidence 0001185185-13-001473 |
| FY 2011 | $-7.5M | 2011-04-01 – 2012-03-31 | evidence 0001185185-12-001484 |
| FY 2010 | $-15.9M | 2010-04-01 – 2011-03-31 | evidence 0001185185-12-001484 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).